San Francisco, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SourcingLink.net (OTC PINK: SNET) is announcing that it will harness the power of pharmacogenomics in its oncology therapy development and clinical trials. Pharmacogenomics studies how the genome influence response to a drug. Dr. Mahant, a SAB member, stated that pharmacogenomics is a "powerful tool" in drug development and clinical trials because pharmacogenomics will allow drug target identification, patient stratification, it will reduce adverse side effects, allow optimal dosing, it will reduce the cost and drug development time, the data will help in any requirements for regulatory submissions and labeling of the drug, and, of course, it will help to "personalize" the drug therapy.
About SourcingLink.net:
SourcingLink.net, Inc. ("SNET") is a pioneering oncology company dedicated to developing , manufacturing and commercialization of therapeutics. SNET licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. SourcingLink.net prides itself for having a world-class Advisory Board that keeps the Company leadership in the forefront of developing technologies in cancer research, biotechnology and healthcare. SourcingLink.net is currently engaging in research and development of therapeutics for oncology. SourcingLink.net is committed to its core corporate mission and values of highest U.S. Pharma Code of Conduct standards of behavior for being in compliance with the laws, regulations, company directives and guidance.
Forward-looking Statements:
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.